Merck & Co., Inc: Vomiting trials

The registry lists 29 Vomiting studies with Merck & Co., Inc as lead sponsor. 0 are open to participants now and 20 have results posted.

Phase 1 6Phase 2 5Phase 3 10Phase 4 6No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)CompletedNCT04054193Phase 4Results posted
• Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)TerminatedNCT02519842Phase 3Results posted
• A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)CompletedNCT01732458Phase 2Results posted
• Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)CompletedNCT01697579Phase 2Results posted
• A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)CompletedNCT01636947Phase 4Results posted
• Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)CompletedNCT01594749Phase 3Results posted
• Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)TerminatedNCT01405924Phase 2Results posted
• A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)CompletedNCT01362530Phase 3Results posted
• Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)CompletedNCT01111851Phase 1Results posted
• Re-examination Study of EMEND (Aprepitant) (MK-0869-184)CompletedNCT01074255Results posted
• A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)CompletedNCT00990821Phase 1Results posted
• Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)CompletedNCT00972595Phase 1Results posted
• A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)CompletedNCT00971633Phase 1Results posted
• Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)CompletedNCT00952341Phase 3Results posted
• A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)CompletedNCT00945321Phase 1Results posted
• A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)TerminatedNCT00818259Phase 1Results posted
• Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)CompletedNCT00619359Phase 3Results posted
• Developing World Study for RotaTeq™ (V260-015)(COMPLETED)CompletedNCT00362648Phase 3Results posted
• Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)CompletedNCT00337727Phase 3Results posted
• A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)CompletedNCT00231777Phase 3Results posted
• Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)CompletedNCT00687011Phase 4
• Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)CompletedNCT00684463Phase 4
• A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)CompletedNCT00539721Phase 2
• A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)CompletedNCT00394966Phase 2
• Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)CompletedNCT00211601Not applicable
• Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)CompletedNCT00092196Phase 3
• An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)CompletedNCT00092183Phase 4
• Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)CompletedNCT00090207Phase 4
• Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)CompletedNCT00080444Phase 3